ArticleTechnical innovations & patient support in radiation oncology2025
Incidental dose to internal mammary nodes in post-operative radiation therapy for breast cancer.
Article in Technical innovations & patient support in radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: The incidental dose to the internal mammary nodes (IMN) is understudied in patients treated with newer radiation therapy (RT) techniques. The aim of this study was to quantify the incidental IMN dose in a series of breast cancer (BC) patients receiving post-operative RT to the chest wall/breast and regional nodes (level III-IV). Methods: We retrospectively analyzed data from 95 high-risk BC patients treated between 2015 and 2022. Patients received RT (50 Gy/25fr or 40.05 Gy/15fr) to the breast/chest wall and nodal levels III-IV after mastectomy or breast conserving surgery (BCS). Exclusion criteria were IMN irradiation and pre-operative systemic therapy. One radiation oncologist contoured the CTV_IMN according to ESTRO guidelines and divided it into four sub-regions based on intercostal spaces (ICS): IMNupper, ICS1, ICS2, ICS3. Dosimetric parameters collected were Dmean, V90, V95, D90, and D95. The Dmean was correlated to tumor laterality and location, type of surgery and reconstruction, RT technique (3D-CRT, IMRT, helical RT) and boost. Results: Mean Dmean to IMN was 71.4 % (range 19.6-118.6) of the prescription dose. Among sub-region, ICS2 and ICS3 received significantly higher doses than ICS1 and IMN upper (p = 0.04). V90 of over 90 % was achieved in only 4/95 patients, 3 were treated with helical RT, and the other with IMRT. The mean V95 and V90 were 15.4 % and 26.2 % respectively. Univariate analysis showed that mastectomy (p = 0.002), omission of boost (p = 0.001), and helical RT (p < 0.0001) were associated with significantly higher IMN Dmean. No significant correlation emerged with laterality, tumor location and type of reconstruction. Conclusions: In our series, incidental IMN doses were highest after mastectomy and with helical RT delivery, possibly due to more medial margin in chest wall delineation and the helical dose distribution. Nevertheless, incidental doses to the IMN were below recommended doses, thus highlighting the need for IMN contouring when identified as targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.